Melissa M Herman, LCSW | |
1312 Highway 49 N, Beulah, ND 58523-6038 | |
(701) 873-4445 | |
(701) 873-4199 |
Full Name | Melissa M Herman |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 1312 Highway 49 N, Beulah, North Dakota |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558502336 | NPI | - | NPPES |
916321044421 | Other | ND | PREFERRED ONE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 3244 (North Dakota) | Primary |
101YA0400X | Counselor - Addiction (substance Use Disorder) | 1665 (North Dakota) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Melissa M Herman, LCSW 1312 Highway 49 N, Beulah, ND 58523-6038 Ph: (701) 873-4445 | Melissa M Herman, LCSW 1312 Highway 49 N, Beulah, ND 58523-6038 Ph: (701) 873-4445 |
News Archive
Inspired by a chemical that fungi secrete to defend their territory, MIT chemists have synthesized and tested several dozen compounds that may hold promise as potential cancer drugs.
Nitrogen is both an essential nutrient and a pollutant, a byproduct of fossil fuel combustion and a fertilizer that feeds billions, a benefit and a hazard, depending on form, location, and quantity. Agriculture, industry and transportation have spread nitrogen liberally around the planet, say sixteen scientists in the latest edition of ESA's Issues in Ecology series, "Excess Nitrogen in the U.S. Environment: Trends, Risks, and Solutions," with complex and interrelated consequences for ecological communities and our dependence upon the resources they provide, as well as human health.
Modular Building Institute has named MedBuild, a healthcare division of ModSpace, first-place winner for their 2010 Awards of Distinction. MBI gave MedBuild top honors in its permanent healthcare category for its construction of the patient-ready imaging suite at Nash General Hospital in Rocky Mount, N.C.
Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, today announced that it has begun enrolling patients in a Phase 2 clinical trial of its lead compound, JVRS-100, as an adjuvant for seasonal influenza vaccines in the elderly population.
Findings presented at the American Stroke Association's International Stroke Conference in Los Angeles revealed that strokes are expected to rise by 350% over the next four decades.
› Verified 1 days ago